Camrelizumab for cancers in patients living with HIV: one-single center experience.

ABSTRACT:

Objectives

The primary objective was to evaluate the safety of the anti-PD-1 antibody camrelizumab in people living with HIV (PLWH); the secondary objective was to evaluate tumor response.

Methods

From May 8, 2018, to December 10, 2021, twenty-four patients with HIV and advanced cancer as well as a CD4⁺ T-cell count greater than or equal to 100 cells/µL were treated with camrelizumab in daily practice. We describe the demographic characteristics, safety, and clinical course of these 24 PLWH with cancer treated with camrelizumab. Safety was assessed using the current Common Terminology Criteria for Adverse Events (CTCAE). The tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

Results

The media

SUBMITTER: Wu M 

PROVIDER: S-EPMC10108516 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature